



PATENT
Attorney Docket No. 056291-5296

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
David Michael ANDREWS, et al.) Confirmation No.: 3394
Application No.: 10/586,954) Group Art Unit: 1614
Filed: July 25, 2006) Examiner: *Unassigned*
For: IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES) Date: April 20, 2007
AS AGENTS FOR THE INHIBITION OF CELL
PROLIFERATION)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §

1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5915
Fax No.: (202) 739-3001

Date: April 20, 2007
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449
April 20, 2007Attorney Docket No.
056291-5296-USApplication No.:
10/586,954Applicants: ANDREWS *et al.*

Filing Date: July 25, 2006

Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
A1	US 4,983,608	January 8, 1991	Effland <i>et al.</i>			
A2	US 5,516,775	May 14, 1996	Zimmerman <i>et al.</i>			
A3	US 5,521,184	May 28, 1996	Zimmermann			
A4	US 5,610,303	March 11, 1997	Kimura <i>et al.</i>			
A5	US 5,739,143	April 14, 1998	Adams <i>et al.</i>			
A6	US 5,859,041	January 12, 1999	Liverton <i>et al.</i>			
A7	US 6,835,726	December 28, 2004	Cushing <i>et al.</i>			
A8	US 20030144303	July 31, 2003	Hawley <i>et al.</i>			
A9	US 20060079543	April 13, 2006	Sum <i>et al.</i>			
A10	US 20030191307	October 9, 2003	Blumenkopf <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
B1	CA 2231765	September 13, 1998	Canada			
B2	EP 0135472	January 18, 1989	EPO			US 4,659,363
B3	EP 0363002	June 22, 1994	EPO			
B4	EP 0379806	April 10, 1996	EPO			
B5	EP 0945443	August 13, 2003	EPO			
B6	EP 1056742	July 23, 2003	EPO			
B7	HU 220630	March 28, 2002	Hungary			Claims
B8	WO 91/18887	December 12, 1991	WIPO			
B9	WO 92/20642	November 26, 1992	WIPO			
B10	WO 95/09847	April 13, 1995	WIPO			
B11	WO 95/09851	April 13, 1995	WIPO			
B12	WO 95/09852	April 13, 1995	WIPO			
B13	WO 95/09853	April 13, 1995	WIPO			
B14	WO 95/15952	June 15, 1995	WIPO			
B15	WO 96/05177	February 22, 1996	WIPO			
B16	WO 96/28427	September 19, 1996	WIPO			
B17	WO 96/40143	December 19, 1996	WIPO			
B18	WO 97/19065	May 29, 1997	WIPO			
B19	WO 97/35856	October 2, 1997	WIPO			
B20	WO 97/40017	October 30, 1997	WIPO			
B21	WO 97/44326	November 27, 1997	WIPO			
B22	WO 9747618	December 18, 1997	WIPO			
B23	WO 98/11095	March 19, 1998	WIPO			
B24	WO 98/16230	April 23, 1998	WIPO			
B25	WO 98/18782	May 7, 1998	WIPO			
B26	WO 98/25619	June 18, 1998	WIPO			
B27	WO 98/33798	August 6, 1998	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)


Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

PTO Form 1449
April 20, 2007



Attorney Docket No.
056291-5296-US

Application No.:
10/586,954

Applicants: ANDREWS *et al.*

Filing Date: July 25, 2006

Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
B28	WO 98/41512	September 24, 1998	WIPO			
B29	WO 98/54093	December 3, 1998	WIPO			
B30	WO 98/56788	December 17, 1998	WIPO			
B31	WO 99/01136	Jan 14, 1999	WIPO			
B32	WO 99/18096	April 22, 1999	WIPO			
B33	WO 99/18942	April 22, 1999	WIPO			
B34	WO 99/31073	June 24, 1999	WIPO			US 6,432,963
B35	WO 99/32121	July 1, 1999	WIPO			
B36	WO 99/41253	August 19, 1999	WIPO			
B37	WO 99/50250	October 7, 1999	WIPO			
B38	WO 99/50251	October 7, 1999	WIPO			
B39	WO 00/12485	March 9, 2000	WIPO			
B40	WO 00/12486	March 9, 2000	WIPO			
B41	WO 00/17202	March 30, 2000	WIPO			
B42	WO 00/17203	March 30, 2000	WIPO			
B43	WO 00/21926	April 20, 2000	WIPO			
B44	WO 00/25780	May 11, 2000	WIPO			
B45	WO 00/26209	May 11, 2000	WIPO			
B46	WO 00/39101	July 6, 2000	WIPO			
B47	WO 00/44750	August 3, 2000	WIPO			
B48	WO 00/49018	August 24, 2000	WIPO			
B49	WO 00/53595	September 14, 2000	WIPO			
B50	WO 00/55161	September 21, 2000	WIPO			
B51	WO 00/59892	October 12, 2000	WIPO			
B52	WO 00/78731	December 28, 2000	WIPO			
B53	WO 01/14375	March 1, 2001	WIPO			
B54	WO 01/29009	April 26, 2001	WIPO			
B55	WO 01/30778	May 3, 2001	WIPO			
B56	WO 01/37835	May 31, 2001	WIPO			
B57	WO 01/47897	July 5, 2001	WIPO			
B58	WO 01/47921	July 5, 2001	WIPO			
B59	WO 01/60816	August 23, 2001	WIPO			
B60	WO 01/64653	September 7, 2001	WIPO			
B61	WO 01/64654	September 7, 2001	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE

(Use several sheets if necessary)

Attorney Docket No.
056291-5296-US

Application No.:
10/586,954

PTO Form 1449
April 20, 2007



Applicants: ANDREWS *et al.*

Filing Date: July 25, 2006

Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date


FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
B62	WO 01/64655	September 7, 2001	WIPO			
B63	WO 01/64656	September 7, 2001	WIPO			
B64	WO 01/72717	October 4, 2001	WIPO			
B65	WO 02/04429	January 17, 2002	WIPO			
B66	WO 02/65979	August 29, 2002	WIPO			
B67	WO 02/66481	August 29, 2002	WIPO			
B68	WO 02/92573	November 21, 2002	WIPO			
B69	WO 02/96887	December 5, 2002	WIPO			
B70	WO 02/96888	December 5, 2002	WIPO			US 20040224966
B71	WO 03/007955	January 30, 2003	WIPO			
B72	WO 03/029249	April 10, 2003	WIPO			
B73	WO 03/031446	April 17, 2003	WIPO			
B74	WO 03/076433	September 18, 2003	WIPO			
B75	WO 03/076434	September 18, 2003	WIPO			
B76	WO 03/076435	September 18, 2003	WIPO			
B77	WO 03/076436	September 18, 2003	WIPO			
B78	WO 04/005283	January 15, 2004	WIPO			
B79	WO 04/043467	May 27, 2004	WIPO			
B80	WO 04/043953	May 27, 2004	WIPO			
B81	WO 04/087698	October 14, 2004	WIPO			
B82	WO 04/087699	October 14, 2004	WIPO			
B83	WO 04/101549	November 25, 2004	WIPO			
B84	WO 04/101564	November 25, 2004	WIPO			
B85	WO 05/012298	February 10, 2005	WIPO			
B86	WO 05/037800	April 28, 2005	WIPO			
B87	WO 05/075468	August 18, 2005	WIPO			
B88	WO 05/113550	December 1, 2005	WIPO			Abstract
B89	WO 05/116025	December 8, 2005	WIPO			
B90	WO 06/034872	April 6, 2006	WIPO			
B91	WO 06/050076	May 11, 2006	WIPO			
B92	WO 06/064251	June 22, 2006	WIPO			
B93	WO 06/075152	July 20, 2006	WIPO			
B94	WO 06/095159	September 14, 2006	WIPO			

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			Attorney Docket No. 056291-5296-US	Application No.: 10/586,954			
 PTO Form 1449 April 20, 2007			Applicants: ANDREWS <i>et al.</i>				
			Filing Date: July 25, 2006	Group Art Unit: 1614			
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	C1	Blain, S. et al. "Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27 ^{Kip1} with cyclin A-Cdk2 and cyclin D2-Cdk4" The Journal of Biological Chemistry, 1997, Vol 272, No.41, pp 25863-25872.					
	C2	Boschelli, D. et al. "Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors" J. Med. Chem., 1998, Vol 41, pp 4365-4377.					
	C3	Deady L. et al. "Reactions of some quinazoline compounds with ethoxymethylenemalonic acid derivatives" J. Heterocyclic Chem., 1989, Vol 26, pp 161-168.					
	C4	El-Kerdawy, M. et al. "2,4-Bis(substituted)-5-nitropyrimidines of expected diuretic action" Egypt. J. Chem., 1986, 29, Vol 2, No. 2, pp 247-251.					
	C5	Fiziol Akt Veshchestva, 1975, 7, pp 68-72.					
	C6	Ghosh, D. et al. "2,4-Bis(arylarnino)-5-methylpyrimidines as antimicrobial agents" J. Med. Chem., 1967, Vol 10, pp 974-975.					
	C7	Ghosh, D., "2,4-Bis(arylarnino)-6-methyl pyrimidines as antimicrobial agents" Chemical Abstracts, 1981, Vol 95, No.11, Columbus, Ohio, US; Abstract No. 97712f; pp 648; XP002109184 abstract & J. Indian Chem. Soc., 1981, Vol 58, No.5, pp 512-513, India.					
	C8	Schmidt, H. et al. "A convenient synthesis of 2-substituted 4-amino-5-pyrimidinecarbonitriles" J. Heterocyclic Chem., 1987, Vol 24, pp 1305-1307.					
	C9	Simone, J. "Oncology: introduction" Bennett, J. Textbook of Medicine, 20th Edition, Vol 1, 1996, pp 1004-1010.					
	C10	Volin, M. et al. "Cell cycle implications in the pathogenesis of rheumatoid arthritis" Frontiers in Bioscience, 2000, 5, d594-601.					
	C11	Zimmermann, J. et al. "Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)" Arch. Pharm. Pharm. Med. Chem. 1996, 329 (7), pp 371-376.					
Examiner		Date Considered					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							